SCHEMBL20119693

SCHEMBL20119693

Clc1nc(NCc2ccncn2)c2nc[nH]c2n1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNH3 Q9ULD8 1/20 0.40
RECQL P46063 1/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
TMIGD3 P0DMS9 1/20 0.36
HTR2C P28335 1/20 0.36
HTR2B P41595 1/20 0.36
CDK2 P24941 4/20 0.35
CCNE1 P24864 3/20 0.35
JAK2 O60674 1/20 0.35
IGF1R P08069 1/20 0.35
PIM1 P11309 1/20 0.35
SRC P12931 1/20 0.35
CSNK2A2 P19784 1/20 0.35
KCNA5 P22460 1/20 0.35
JAK1 P23458 1/20 0.35
TYK2 P29597 1/20 0.35
FLT4 P35916 1/20 0.35
FLT3 P36888 1/20 0.35
MAP3K8 P41279 1/20 0.35
CSNK1A1 P48729 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20119459 0.83 RECQL (0.51) RECQLSMN1; SMN2TMIGD3HTR2CHTR2B
SCHEMBL20119583 0.83 TMIGD3 (0.43) SMN1; SMN2TMIGD3HTR2CHTR2BCDK2
SCHEMBL15950875 0.81 RECQL (0.45) KCNH3RECQLSMN1; SMN2CDK2JAK2
SCHEMBL20119917 0.81 MAP4K4 (0.38) RECQLSMN1; SMN2TMIGD3HTR2CHTR2B
SCHEMBL20119640 0.80 KCNH3 (0.40) KCNH3CDK2CCNE1JAK2IGF1R
SCHEMBL20119909 0.79 CDK2 (0.39) KCNH3RECQLSMN1; SMN2TMIGD3HTR2C
SCHEMBL20119597 0.79 LMNA (0.38) SMN1; SMN2TMIGD3HTR2CHTR2BCDK2
SCHEMBL25873886 0.78 KCNH3 (0.37) KCNH3CDK2CCNE1JAK2IGF1R
SCHEMBL20119926 0.78 KCNH3 (0.37) KCNH3CDK2CCNE1JAK2IGF1R
SCHEMBL20119892 0.78 KCNH3 (0.43) KCNH3SMN1; SMN2CDK2CCNE1JAK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230279007-A1 Compounds for Improving mRNA Splicing THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES 2023-09-07 US disclosed
US-20230279007-A1 Compounds for Improving mRNA Splicing THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES 2023-09-07 US disclosed
US-11702417-B2 Compounds for improving mRNA splicing THE GENERAL HOSPITAL CORPORATION (US) 2023-07-18 US disclosed
US-11702417-B2 Compounds for improving mRNA splicing THE GENERAL HOSPITAL CORPORATION (US) 2023-07-18 US disclosed
US-20200283441-A1 Compounds for Improving mRNA Splicing THE GENERAL HOSPITAL CORPORATION 2020-09-10 US disclosed
US-10676475-B2 Compounds for improving mRNA splicing THE GENERAL HOSPITAL CORPORATION (US) 2020-06-09 US disclosed
US-20180118748-A1 Compounds for Improving mRNA Splicing THE GENERAL HOSPITAL CORPORATION 2018-05-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230279007-A1 Compounds for Improving mRNA Splicing RTCB, RBM17, HNRNPA2B1 KCNH3 3654/4885RECQL 1005/4885SMN1; SMN2 11/4885
US-10676475-B2 Compounds for improving mRNA splicing RTCB, RBM17, HNRNPA2B1 KCNH3 3654/4885RECQL 1005/4885SMN1; SMN2 11/4885
US-20180118748-A1 Compounds for Improving mRNA Splicing RTCB, RBM17, HNRNPA2B1 KCNH3 3654/4885RECQL 1005/4885SMN1; SMN2 11/4885
US-11702417-B2 Compounds for improving mRNA splicing RTCB, RBM17, HNRNPA2B1 KCNH3 3654/4885RECQL 1005/4885SMN1; SMN2 11/4885
US-20200283441-A1 Compounds for Improving mRNA Splicing RTCB, RBM17, HNRNPA2B1 KCNH3 3654/4885RECQL 1005/4885SMN1; SMN2 11/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.